Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine

Next Previous
X
Search
Trial Profile

A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Sponsors Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals; Pfizer

    • Most Recent Events

    • 10 Dec 2022 Results evaluating the safety and tolerability of rimegepant in adults with cardiovascular (CV) risk factors, presented at the 16th European headache federation COngress
    • 13 Jun 2022 According to a Biohaven Pharmaceuticals Media Release, data from this study were presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS)
    • 13 Jun 2022 Results published in the Biohaven Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top